Radicle Rest 2: A Study of Health and Wellness Products on Sleep and Health Outcomes

Last updated: May 17, 2024
Sponsor: Radicle Science
Overall Status: Completed

Phase

N/A

Condition

Insomnia

Sleep Disorders

Restless Leg Syndrome

Treatment

Rest Study Active Product 2.1 Usage

Rest Study Active Product 4.2 Usage

Placebo Control Form 3

Clinical Study ID

NCT05657808
RADX-2301
  • Ages 21-105
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A randomized, blinded, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on sleep and other health outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults, 21 years of age and older at the time of electronic consent, inclusive ofall ethnicities, races, genders and/or gender identities

  • Resides in the United States

  • Endorses better sleep as a primary desire

  • Selects sleep, looking to improve their sleep, and/or reduce reliance on medicationsas a reason for their interest in taking a health and wellness product

  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion

Exclusion Criteria:

  • Reports being pregnant, trying to become pregnant, or breastfeeding

  • Unable to provide a valid US shipping address

  • The calculated validated health survey (PRO) measurement result is less than mildseverity/impairment

  • Reports a diagnosis of liver or kidney disease

  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages perday)

  • Unable to read and understand English

  • Reports current enrollment in a clinical trial

  • Lack of reliable daily access to the internet

  • Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, ororal anti-infectives (antibiotics, antifungals, antivirals) to treat an acuteinfection

  • Reports taking medications with a known moderate or severe interaction with any ofthe active ingredients studied: anticoagulants, a medication that warns againstgrapefruit consumption, corticosteroids at doses greater than 5 mgs per day, ormonoamine oxidase inhibitors (MAOIs)

  • Reports a diagnosis of heart disease when a known contraindication exists for any ofthe active ingredients studied: New York Heart Association (NYHA) Class III or IVcongestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias

Study Design

Total Participants: 4152
Treatment Group(s): 12
Primary Treatment: Rest Study Active Product 2.1 Usage
Phase:
Study Start date:
January 09, 2023
Estimated Completion Date:
April 15, 2024

Study Description

This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for improved sleep, (2) indicate an interest in taking a health and wellness product to potentially help their sleep, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.

Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Connect with a study center

  • Radicle Science, Inc

    Del Mar, California 92014
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.